




Form PTO 449  US Department of Commerce Patent and Trademark Office	ATTY CLIENT- MATTER NO: 66778-120	SERIAL NO. 10/616,897
	APPLICANT: Ingraham and Krylova	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: July 9, 2003	GROUP: 1646

#### U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
		4,959,314	9/25/90	Mark et al.	435	69.1	2/7/85

#### FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION (YES/NO)

#### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

		Crawford et al., "The Activation Function-2 Hexamer of Steroidogenic Factor-1 Is Required, but Not Sufficient for Potentiation by SRC-1," <u>Mol. Endocrinol.</u> 11:1626-1635 (1997).
		Egea et al., "Crystal structure of the human RXR $\alpha$ ligand-binding domain bound to its natural ligand: 9-cis retinoic acid," <u>EMBO J.</u> 19:2592-2601 (2000).
		Evans, "The Steroid and Thyroid Hormone Receptor Superfamily," <u>Science</u> 240:889-895 (1988).
		Forman et al., "Androstane metabolites bind to and deactivate the nuclear receptor CAR- $\beta$ ," <u>Nature</u> 395:612-615 (1998).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO 1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: 66778-120	SERIAL NO. 10/616,897
	APPLICANT: Ingraham and Krylova	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: July 9, 2003	GROUP: 1646

	Gangloff et al., "Crystal Structure of a Mutant hER $\alpha$ Ligand-binding Domain Reveals Key Structural Features for the Mechanism of Partial Agonism," <u>J. Biol. Chem.</u> 276:15059-15065 (2001).
	Geistlinger and Guy, "An Inhibitor of the Interaction of Thyroid Hormone Receptor $\beta$ and Glucocorticoid Interacting Protein 1," <u>J. Am. Chem. Soc.</u> 123:1525-1526 (2001).
	Hammer and Ingraham, "Steroidogenic Factor-1: Its Role in Endocrine Organ Development and Differentiation," <u>Front. Neuroendocrinol.</u> 20: 199-223 (1999).
	Hammer et al., "Phosphorylation of the Nuclear Receptor SF-1 Modulates Cofactor Recruitment: Integration of Hormone Signaling in Reproduction and Stress," <u>Mol. Cell.</u> 3:521-526 (1999).
	Ikeda et al., "Characterization of the Mouse <i>FTZ-F1</i> Gene, Which Encodes a Key Regulator of Steroid Hydroxylase Gene Expression," <u>Mol. Endocrinol.</u> 7:852-860 (1993).
	Ito et al., "DAX-1 Inhibits SF-1-Mediated Transactivation via a Carboxy-Terminal Domain That Is Deleted in Adrenal Hypoplasia Congenita," <u>Mol. Cell Biol.</u> 17:1476-1483 (1997).
	Lala et al., "Activation of the orphan nuclear receptor steroidogenic factor 1 by oxysterols," <u>Proc. Natl. Acad. Sci. USA</u> 94:4895-4900 (1997).
	Lala et al., "Steroidogenic Factor I, a Key Regulator of Steroidogenic Enzyme Expression, Is the Mouse Homolog of <i>fushi tarazu</i> -Factor I," <u>Molecular Endocrinology</u> 6:1249-1258 (1992).
	Li et al., "Cloning and Characterization of a Novel Human Hepatocyte Transcription Factor, hB1F, Which Binds and Activates Enhancer II of Hepatitis B Virus," <u>J. Biol. Chem.</u> 273:29022-29031 (1998).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

